DaVita management check
DVA · Health Care · Health Care Services · CEO Javier J. Rodriguez
Filings as of
4 good · 3 to watch · 0 flagged, across the seven questions below.
- Watch
Have owners done well?
Trailed its chosen peers$100 invested at the start of fiscal 2021 grew to $97, against $113 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.83 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch
What does the CEO cost owners?
1.7% of net income$18.2m of reported pay in fiscal 2025, against $1.1bn of net income.
- Watch
Do they own the stock?
CEO stake ≈ 10 years of payThe CEO holds 879,815 shares, directly or through trusts (unvested awards not counted): about 10 years of pay. 5 insiders sold $35.0m in the last six months and none bought.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -9.8% a year over the last three fiscal years. Stock-based pay was 1.0% of revenue in the latest year.
- Good
Is leadership stable?
2 leadership filings in 3 yearsCEO in the pay table: Javier J. Rodriguez. 2 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 32 | 26 | |
| Pay for performance | 92 | 85 | |
| CEO cost | 31 | 44 | |
| Skin in the game | 65 | 46 | |
| Dilution | 100 | 68 | |
| Stable leadership | 100 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Health Care Services, by management score. DaVita is 12th of 60 in its sector.
- 110CICigna76
- 115ABTAbbott Laboratories75
- 124DVADaVita74
- 194LHLabcorp69
- 219DGXQuest Diagnostics67
- 362CVSCVS Health57
Pay versus performance
From the proxy statement filed April 22, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Javier J. Rodriguez | $18.2m | $18.9m | $4.4m | $97 | $113 | $1.1bn |
| 2024 | Javier J. Rodriguez | $21.8m | $20.6m | $5.3m | $127 | $95 | $1.3bn |
| 2023 | Javier J. Rodriguez | $6.7m | $4.8m | $6.4m | $89 | $93 | $957.0m |
| 2022 | Javier J. Rodriguez | $3.0m | −$86.4m | $4.2m | $64 | $88 | $781.6m |
| 2021 | Javier J. Rodriguez | $3.3m | −$13.1m | $4.3m | $97 | $110 | $1.2bn |
The board says pay is tied most to Adjusted Earnings per Share. Its other key measures: Free cash flow, Adjusted operating income, Total shareholder return.
Insiders and the CEO's stake
Javier Rodriguez (Chief Executive Officer) held 879,815 shares directly after their latest Form 4 on Jun 16, 2026, roughly $184.1m at that filing's price.
5 insiders sold $35.0m in the last six months and none bought.
- SoldJavier RodriguezChief Executive Officer$14.5mJun 16, 2026
- SoldJoel AckermanCFO and Treasurer$9.9mMay 7, 2026
- SoldDavid Paul MaughanChief Operating Officer, DKC$4.1mMay 12, 2026
- SoldJames O HeartyChief Compliance Officer$3.3mMay 15, 2026
Leadership and governance on file
- Sep 13, 2024Leadership change8-K 5.02
- Apr 10, 2024Leadership change8-K 5.02
- Jul 25, 2023Leadership change8-K 5.02
- Jul 13, 2023Leadership change8-K 5.02
- Mar 21, 2023Leadership change8-K 5.02
- Sep 13, 2022Leadership change8-K 5.02
- Apr 8, 2022Leadership change8-K 5.02
Latest shareholder vote results: Jun 8, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $5.3bn returned to owners in buybacks and dividends, 101% of net income, and $552.8m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $11.6bn | $11.6bn | $12.1bn | $12.8bn | $13.6bn |
| Net income | $1.2bn | $781.6m | $957.0m | $1.3bn | $1.1bn |
| Stock-based pay | $102.2m | $95.4m | $112.4m | $102.8m | $140.0m |
| Buybacks | $1.5bn | $802.2m | $272.2m | $1.4bn | $1.3bn |
| Dividends | $0 | $0 | $0 | $0 | $0 |
| Diluted shares | 110m | 96m | 93m | 87m | 76m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.